Logo

Sorrento's Resiniferatoxin Receives the US FDA's Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with Osteoarthritis

Share this

Sorrento's Resiniferatoxin Receives the US FDA's Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with Osteoarthritis

Shots:

  • The P-II trial will assess the efficacy & safety of RTX across several dose groups vs PBO in patients with a mod. to sev. OAK pain. The study follows the P-Ib trial results of RTX
  • The P-Ib data demonstrated the significant efficacy supporting RTX for long term refractory OA pain- pain relief observed in patients with advanced OA disease- and sustained pain relief last beyond 6 mos.
  • The program continues with P-II & P-III trial in larger patient populations- while the P-II trial will be targeted to identify the RP3D. The company has decided to add an active comparator (injectable corticosteroid) in the current trial protocol to give the durability of OA pain relief response

  Ref: GlobeNewswire | Image: Analyze Markets

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions